NCT00681603

Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization

The Application of Subconjunctival Injection of Bevacizumab (Avastin) in the Treatment of Corneal Neovasculization

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: National Taiwan University Hospital · Academic / Other
• Sex: —
• Age: 10 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

1. Purpose:Our animal study demonstrated the effectiveness of subconjunctival injection of bevacizumab in the inhibition of corneal neovasculization formation. The purpose of this human interventional study is to report the treatment outcome of subconjunctival injection of bevacizumab in patients with corneal neovascularization. 2. Material and methods: We enrolled 13 patients with unilateral or bilateral clinically significant corneal neovascularization during Aug. 2007 to Jan. 2008. Subconjunctival injection of bevacizumab once per month for at most 7 times was performed according to clinical response. 3. Main outcome measurements: resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity.

Conditions

• Lipid Keratopathy
• Penetrating Keratoplasty
• Herpetic Keratopathy
• Rosacea

Interventions

Type	Name	Description
DRUG	subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)	subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.

Timeline

• Start date: 2007-08-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2008-05-21
• Last updated: 2008-05-21

Locations

1 site across 1 country: Taiwan